Northwestern University Lead Academic Participating Site Supplement Year 2

西北大学主导学术参与网站补充第二年

• 批准号: 10299729
• 负责人: AL B BENSON
• 金额: $ 31.5万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-04-01 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10299729
• 关键词: Advanced Malignant Neoplasm; American College of Radiology Imaging Network; Ancillary Study; Area; Cancer Intervention; Chicago; Clinical Research; Clinical Trials; Collaborations; Comprehensive Cancer Center; Eastern Cooperative Oncology Group; Faculty; Goals; Home; Infrastructure; Institution; International; Lead; Leadership; Malignant Neoplasms; Patient Recruitments; Patients; Recording of previous events; Research Infrastructure; Resources; Role; Science; Scientific Advances and Accomplishments; Site; Southwest Oncology Group; Universities; data quality; improved; inter-institutional; metropolitan; recruit; senior faculty

Summary/Abstract: The Robert H. Lurie Comprehensive Cancer Center of Northwestern University (LCC) has a long history of NCTN participation with ECOG membership since 1973. Currently, the LCC infrastructure supports participation in clinical trials and ancillary studies through the ECOG-ACRIN, SWOG, Alliance, NRG and COG. Recognized for accrual, participation and high-level of data quality, the LCC has been selected by the NCTN leadership to participate in the High Performing Site Initiative (HPSI) in 2015, 2016 and 2017 to support our infrastructure and to enable continued participation in NCTN trials. In 2019, Northwestern University was designated as a Lead Academic Performing site (LAPS) and in this new role continues to significantly accrue patients to NCTN trials, exceeding planned accrual goals in both years as a LAPS institution. Through continued demonstration of significant scientific accomplishments and new initiatives, recruitment of accomplished senior faculty and productive junior faculty, comprehensive and integrated infrastructure for oversight of cancer-related clinical trials, LCC will continue to expand participation in NCTN trials, provide scientific leadership of key network activities, and increase inter-institutional collaborations and access to unique scientific resources, to advance cancer interventions.

总结/摘要： 罗伯特·H。西北大学Lurie综合癌症中心（LCC）有着悠久的NCTN历史 自1973年以来一直是联合国西非经济共同体成员。目前，LCC基础设施支持参与 通过ECOG-ACRIN、SWOG、Alliance、NRG和COG进行的临床试验和辅助研究。认可 应计、参与和高水平的数据质量，LCC已被NCTN领导层选中， 在2015年、2016年和2017年参与高性能站点计划（HPSI），以支持我们的基础设施， 以便继续参与NCTN试验。 在2019年，西北大学被指定为领先的学术表演网站（LAPS），并在这个新的 NCTN试验的患者继续显著增加，超过了两年的计划增加目标， LAPS机构。 通过不断展示重大科学成就和新举措， 有成就的高级教师和富有成效的初级教师，全面综合的基础设施， 为了监督癌症相关临床试验，LCC将继续扩大参与NCTN试验， 关键网络活动的科学领导，并增加机构间合作和获得独特的 科学资源，以推进癌症干预。